[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615885":3},{"organization":4,"outcomesModule":7,"designInfo":43,"detailedDescription":11,"studyPopulation":11,"armGroups":54,"interventions":65,"overallOfficials":75,"centralContacts":79,"locations":87,"responsibleParty":229,"collaborators":11,"id":231,"slug":232,"hasResults":233,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":233,"sex":239,"minAge":240,"maxAge":241,"enrollmentInfo":242,"targetDuration":11,"studyType":245,"phases":246,"briefSummary":248,"conditions":249,"keywords":11,"overallStatus":90,"whyStopped":11,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":260},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Percentage of Participants With Clinical Remission per Pediatric Crohn's Disease Activity Index (PCDAI)",null,"At Week 52",{"measure":14,"description":11,"timeFrame":12},"Percentage of Participants With Endoscopic Response",[16,19,21,23,26,28,30,32,34,36,38,41],{"measure":17,"description":11,"timeFrame":18},"Percentage of Participants With Clinical Remission","At Week 12 and Week 52",{"measure":20,"description":11,"timeFrame":18},"Percentage of Participants With Clinical Response",{"measure":22,"description":11,"timeFrame":18},"Percentage of Participants With CDAI Remission",{"measure":24,"description":11,"timeFrame":25},"Change From Baseline in Fecal Calprotectin","Baseline, Week 12 and Week 52",{"measure":27,"description":11,"timeFrame":25},"Change From Baseline in Mucosal Inflammation Noninvasive Index (MINI) Score",{"measure":29,"description":11,"timeFrame":12},"Percentage of Participants With Endoscopic Remission",{"measure":31,"description":11,"timeFrame":12},"Percentage of Participants With Corticosteroid-Free Clinical Remission",{"measure":33,"description":11,"timeFrame":18},"Percentage of Participants with Maintenance of Remission",{"measure":35,"description":11,"timeFrame":12},"Percentage of Participants With Histologic Improvement",{"measure":37,"description":11,"timeFrame":12},"Percentage of Participants With Ulcer-Free Endoscopy",{"measure":39,"description":11,"timeFrame":40},"Incidence and Severity of Adverse Events (AEs)","Up to Approximately 5.5 Years",{"measure":42,"description":11,"timeFrame":40},"Serum Concentration of Afimkibart",{"allocation":44,"interventionModel":45,"interventionModelDescription":11,"primaryPurpose":46,"observationalModel":11,"timePerspective":11,"maskingInfo":47},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":48,"maskingDescription":11,"whoMasked":49},"QUADRUPLE",[50,51,52,53],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[55,61],{"label":56,"type":57,"description":58,"interventionNames":59},"Afimkibart Dose A","EXPERIMENTAL","Participants will receive Afimkibart intravenously (IV) followed by Afimkibart subcutaneous (SC) injection.",[60],"Drug: Afimkibart",{"label":62,"type":57,"description":63,"interventionNames":64},"Afimkibart Dose B","Participants will receive Afimkibart IV followed by Afimkibart SC.",[60],[66],{"type":67,"name":68,"description":69,"armGroupLabels":70,"otherNames":71},"DRUG","Afimkibart","Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.",[56,62],[72,73,74],"RO7790121","PF-06480605","RVT-3101",[76],{"name":77,"affiliation":5,"role":78},"Clinical Trials","STUDY_DIRECTOR",[80,85],{"name":81,"role":82,"phone":83,"phoneExt":11,"email":84},"Reference Study ID Number: CP45906 https:\u002F\u002Fforpatients.roche.com\u002F No attachments to email below.","CONTACT","888-662-6728 (U.S. and Canada)","global-roche-genentech-trials@gene.com",{"name":86,"role":82,"phone":11,"phoneExt":11,"email":11},"Fastest response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[88,101,113,123,135,143,155,164,176,185,196,207,213,218],{"facility":89,"status":90,"city":91,"state":91,"zip":92,"country":93,"countryCode":94,"cosmosGeoPoint":95,"geoPoint":100,"contacts":11},"NYU Langone Health","RECRUITING","New York","10016","United States","US",{"type":96,"coordinates":97},"Point",[98,99],-74.00597,40.71427,{"lat":99,"lon":98},{"facility":102,"status":90,"city":103,"state":104,"zip":105,"country":106,"countryCode":107,"cosmosGeoPoint":108,"geoPoint":112,"contacts":11},"Royal Children's Hospital","Parkville","Victoria","3052","Australia","AU",{"type":96,"coordinates":109},[110,111],144.95,-37.78333,{"lat":111,"lon":110},{"facility":114,"status":90,"city":115,"state":116,"zip":117,"country":106,"countryCode":107,"cosmosGeoPoint":118,"geoPoint":122,"contacts":11},"Perth Children's Hospital","Nedlands","Western Australia","6009",{"type":96,"coordinates":119},[120,121],115.8073,-31.98184,{"lat":121,"lon":120},{"facility":124,"status":90,"city":125,"state":126,"zip":127,"country":128,"countryCode":129,"cosmosGeoPoint":130,"geoPoint":134,"contacts":11},"CECIP - Centro de Estudos Clínicos do Interior Paulista","Jaú","São Paulo","17201-130","Brazil","BR",{"type":96,"coordinates":131},[132,133],-48.55778,-22.29639,{"lat":133,"lon":132},{"facility":136,"status":90,"city":126,"state":126,"zip":137,"country":128,"countryCode":129,"cosmosGeoPoint":138,"geoPoint":142,"contacts":11},"BR Trials - Pesquisa Clínica","01236-030",{"type":96,"coordinates":139},[140,141],-46.63611,-23.5475,{"lat":141,"lon":140},{"facility":144,"status":90,"city":145,"state":146,"zip":147,"country":148,"countryCode":149,"cosmosGeoPoint":150,"geoPoint":154,"contacts":11},"Centro de Investigación Clínica Acelerada, S.C","Mexico City","Mexico CITY (federal District)","07369","Mexico","MX",{"type":96,"coordinates":151},[152,153],-99.12766,19.42847,{"lat":153,"lon":152},{"facility":156,"status":90,"city":157,"state":11,"zip":158,"country":148,"countryCode":149,"cosmosGeoPoint":159,"geoPoint":163,"contacts":11},"FAICIC Clinical Research","Veracruz","91900",{"type":96,"coordinates":160},[161,162],-96.1429,19.18095,{"lat":162,"lon":161},{"facility":165,"status":90,"city":166,"state":167,"zip":168,"country":169,"countryCode":170,"cosmosGeoPoint":171,"geoPoint":175,"contacts":11},"Emmed Research","Pretoria","Gauteng","84","South Africa","ZA",{"type":96,"coordinates":172},[173,174],28.18783,-25.74486,{"lat":174,"lon":173},{"facility":177,"status":90,"city":178,"state":11,"zip":179,"country":169,"countryCode":170,"cosmosGeoPoint":180,"geoPoint":184,"contacts":11},"IATROS International","Bloemfontein","9301",{"type":96,"coordinates":181},[182,183],26.214,-29.12107,{"lat":183,"lon":182},{"facility":186,"status":90,"city":187,"state":11,"zip":188,"country":189,"countryCode":190,"cosmosGeoPoint":191,"geoPoint":195,"contacts":11},"National Taiwan University Hospital","Taipei","100","Taiwan","TW",{"type":96,"coordinates":192},[193,194],121.52639,25.05306,{"lat":194,"lon":193},{"facility":197,"status":90,"city":198,"state":11,"zip":199,"country":200,"countryCode":201,"cosmosGeoPoint":202,"geoPoint":206,"contacts":11},"Chulalongkorn University","Bangkok","10330","Thailand","TH",{"type":96,"coordinates":203},[204,205],100.50144,13.75398,{"lat":205,"lon":204},{"facility":208,"status":90,"city":198,"state":11,"zip":209,"country":200,"countryCode":201,"cosmosGeoPoint":210,"geoPoint":212,"contacts":11},"Siriraj Hospital","10700",{"type":96,"coordinates":211},[204,205],{"lat":205,"lon":204},{"facility":214,"status":90,"city":198,"state":11,"zip":11,"country":200,"countryCode":201,"cosmosGeoPoint":215,"geoPoint":217,"contacts":11},"Ramathibodi Hospital",{"type":96,"coordinates":216},[204,205],{"lat":205,"lon":204},{"facility":219,"status":90,"city":220,"state":11,"zip":221,"country":222,"countryCode":223,"cosmosGeoPoint":224,"geoPoint":228,"contacts":11},"Sheffield Childrens Hospital","Sheffield","S10 2TH","United Kingdom","UK",{"type":96,"coordinates":225},[226,227],-1.4659,53.38297,{"lat":227,"lon":226},{"type":230,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100615885","a-study-to-assess-the-pharmacokinetics-effectiveness-and-safety-of-afimkibart-for-induction-and-maintenance-therapy-in-children-with-moderately-to-severely-active-crohns-disease-100615885",false,"NCT07298421","A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease","A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2-17 Years With Moderately to Severely Active Crohn's Disease","SIBERITE-PEDS","Inclusion Criteria:\n\n* Body weight \\>= 10 kilogram (kg)\n* Active CD confirmed by endoscopy (ileocolonoscopy)\n* Moderately to severely active CD, defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score \\>= 30, and Simple Endoscopic Score Crohn's Disease (SES-CD) \\>=6 (or \\>=4 for isolated ileal disease) confirmed through centrally-read ileocolonoscopy\n* Inadequate response, loss of response, and\u002For intolerance to at least one of the following conventional therapies (aminosalicylates, corticosteroids and\u002For immunosuppressants) or advanced therapies (including anti-tumor necrosis factor, anti-interleukin, anti-integrin, or Janus Kinase (JAK) inhibitors)\n\nExclusion Criteria:\n\n* Monogenic disorder pertaining to infant onset Inflammatory Bowel Disease (IBD)\n* History of \\>= 3 bowel resections: \\> 2 missing segments of the following five segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum\n* Current diagnosis of ulcerative colitis (UC), abdominal\u002Fintraabdominal\u002Fperianal fistula and\u002For abscess, indeterminant colitis, IBD-unclassified, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, or active diverticular disease.\n* Symptomatic bowel strictures, fulminant colitis, or toxic megacolon\n* Presence of abdominal or perianal abscess\n* Current diagnosis or suspicion of primary sclerosing cholangitis","ALL","2 Years","17 Years",{"count":243,"type":244},100,"ESTIMATED","INTERVENTIONAL",[247],"PHASE3","This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).",[250],"Moderately to Severely Active Crohns Disease","2026-09-04",{"date":253,"type":254},"2026-09-08","ACTUAL",{"date":256,"type":254},"2026-08-18",{"date":258,"type":244},"2031-05-30",{"name":5,"class":6},14]